CEO Donna LaVoie was recently featured in 
European Biopharmaceutical News, highlighting the Public Relations Renaissance and why integrated media platforms have a key role to play.
“Whether your company is a large pharmaceutical, speciality pharmaceutical or biotechnology company, the effective integration of public and investor relations is critical in today’s ever-changing environment.
The advent of the internet and the digital world has altered the field forever and as such communications functions have altered immensely. Today, with the prevalence of Web 2.0 (web applications that facilitate interactive information sharing) and Web 3.0 (the personalisation of web applications) as integral pieces of the communications discipline; the need to work across key functional areas within communications and other key work streams such as regulatory, legal and medical affairs has been highlighted.
Traditional PR tactics have rules and expectations that are usually followed to the letter. For news announcements, PR firms generally recommend selecting a date around launches, milestones and/or conferences, issue the news at 08:30 on a particular day and then monitor print publications for resulting stories. If the article was negative, the PR firm would call that reporter and request a correction (if possible). In today’s Web 2.0 reality, these rules of engagement no longer apply, and press releases are no longer handled as a ‘one size fits all’ solution.”
Read up on the rest of Donna’s insights here.
